2025 International Fall Summit
October 15, 2025 | 12:00 PM EST
- Home
- Clinical Resources Search
- PQI in Action: Management of Tucatinib (Tukysa®) and Trastuzumab in HER2-Positive Metastatic Colorectal Cancer – 2
Management of Tucatinib (Tukysa®) and Trastuzumab in HER2-Positive Metastatic Colorectal Cancer
Download PQI pdf 1.5MB
Last Updated: July 28, 2025
By: Johns Hopkins, MD | The University of Texas MD Anderson Cancer Center, TX
About this PQI in Action
In an effort to promote higher quality patient care, NCODA created the NCODA Positive Quality Intervention (PQI) as a peer-reviewed clinical guidance resource for healthcare providers. By providing Quality Standards and effective practices around a specific aspect of cancer care, PQIs equip the entire multidisciplinary care team with a sophisticated yet concise resource for managing patients receiving oral or IV oncolytics. This PQI in Action explores how the medically integrated teams at the Ruesch Center for the Cure of GI Cancers at Georgetown University and University Hospitals Seidman Cancer Center incorporate the information found in the PQIs as part of their daily workflow. This article will discuss how utilizing the Tucatinib (TUKYSA®) and trastuzumab in HER2-positive Metastatic Colorectal Cancer PQI elevates patient care.
More About This PQI in Action
Find a PQIPQI
PQI: Tucatinib (TUKYSA®) and trastuzumab in HER2-positive Metastatic Colorectal Cancer
Last Updated: 01/08/2024